Purpose Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a severe complication of SSc, characterised by progressive fibrosis and inflammation. Current diagnostic tools do not accurately differentiate progressors from non-progressors, limiting timely intervention. 68Ga-FAPI-46 is a positron emission tomography (PET) tracer targeting fibroblast activation protein alpha (FAP), a marker of activated fibroblasts, with high affinity and retention. Optimal imaging timepoints and PET parameters for 68Ga-FAPI-46 PET/CT imaging in fibroinflammatory disorders remain undefined. This exploratory study investigated early versus late 68Ga-FAPI-46 PET parameters in evaluating SSc-ILD. Methods Early (10 min) and late (60 min) 68Ga-FAPI-46 PET parameters were compared between progressive (n = 8) and non-progressive SSc-ILD (n = 14), defined by INBUILD trial criteria. PET parameters were correlated with pulmonary function test (PFT) and HRCT parameters. Optimal thresholds for identified PET parameters were determined by closest-to-(0,1) criterion. Results Early total lesion FAPI uptake (median TL-FAPI10min 1245 vs. 714, p = 0.020) and affected lung volume (median AV10min 514 ml vs. 368 ml, p = 0.042) were significantly higher in progressors than non-progressors. Early PET parameters showed stronger, more consistent correlations with PFT and quantitative HRCT parameters than late PET parameters. Volume-based compared to intensity-based PET parameters more consistently correlated with PFT and quantitative HRCT parameters. TL-FAPI10min threshold of 928 had the best diagnostic performance (AUC 0.80). Conclusion This exploratory study showed that 68Ga-FAPI-46 PET/CT imaging, specifically early volume-based PET parameters, was associated with patients with recent disease progression of SSc-ILD. Prospective validation in treatment-response studies is needed to confirm the clinical utility of these PET parameters and their identified preliminary thresholds.
Background: Metabotropic glutamate receptor subtype 5 (mGluR5) is a promising therapeutic target for a range of neuropsychiatric disorders, and [18F]FPEB is a PET radioligand developed for imaging central mGluR5 receptor availability. This study aimed to determine the biodistribution, kinetic characteristics, and radiation dosimetry of [18F]FPEB in healthy Asian subjects and to evaluate the feasibility of reference tissue models as alternatives to conventional blood-based kinetic modeling. Methods: Five healthy Asian male volunteers underwent whole-body and dynamic brain PET imaging following administration of [18F]FPEB. Radiation dosimetry was estimated using OLINDA/EXM software. Tracer kinetics were analyzed using both blood-based compartmental models and reference tissue models to derive regional binding potentials (BPND) and volumes of distribution. Model performance was assessed using the Akaike Information Criterion (AIC). Results: The mean whole-body effective radiation dose was 0.703 mSv/mCi, with the gallbladder identified as the critical organ receiving the highest absorbed dose (5.63 mGy/mCi). Brain time–activity curves demonstrated the highest tracer uptake in the nucleus accumbens, followed by the cingulate gyrus, putamen, and insula, with moderate uptake in the thalamus and globus pallidus and the lowest uptake in the brainstem and cerebellum. Using the simplified reference tissue models (SRTM/SRTM2), the highest BPND values were observed in the nucleus accumbens, followed by the cingulate gyrus, putamen, and insula. In contrast, two-tissue compartment models (2TCM/2TCM-C) showed the highest BPND values in the hippocampus, followed by the amygdala, nucleus accumbens, and caudate nucleus. Although differences were observed in the absolute BPND values and regional ranking, both modeling approaches identified similar brain regions with high mGluR5 binding. Conclusions: [18F]FPEB demonstrated a favorable radiation dosimetry profile and supports the feasibility of reference tissue models for BPND estimation in healthy Asian subjects. These findings provide preliminary baseline data, although validation in larger cohorts is needed to confirm the pharmacokinetic characteristics and modeling approach.